Literature DB >> 23160483

A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).

Maria R Tellez1, Gregg Mamikunian, Thomas M O'Dorisio, Aaron I Vinik, Eugene A Woltering.   

Abstract

OBJECTIVES: 5-Hydroxyindoleacetic acid (5-HIAA) is used for the evaluation of neuroendocrine tumors (NETs) but currently requires a 24-hour urine collection.
METHODS: We developed a gas chromatography mass spectroscopy-based plasma 5-HIAA assay. We compared 24-hour urine 5-HIAA values against plasma 5-HIAA values in 115 mixed-variety patients with NETs and in a subset of 72 patients with only small bowel NETs. We also compared the information gained from urinary and plasma 5-HIAA values with other biomarkers of midgut NET activity to determine the plasma assay's clinical implications.
RESULTS: In a group of 115 patients with all types of NETS, in a subset of patients with midgut NET and in a subgroup of midgut NETS with liver metastasis, the correlation between the urine and fasting plasma 5-HIAA values were statistically significant (P ≤ 0.0001). Comparison of the proportion of normal or abnormal urinary and plasma 5-HIAA values to the proportion of chromogranin, serotonin, neurokinin, or pancreastatin values that were in the normal or abnormal range yielded essentially identical information.
CONCLUSIONS: Plasma fasting 5-HIAA values are proportional to urinary 5-HIAA values and yielded identical clinical correlation with other biomarkers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23160483     DOI: 10.1097/MPA.0b013e318271c0d5

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  16 in total

Review 1.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 2.  Carcinoid Syndrome: Updates and Review of Current Therapy.

Authors:  Kira Oleinikov; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2019-07-09

Review 3.  Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

Authors:  Christian Fottner; Martina Ferrata; Matthias M Weber
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 4.  Recent Trends in the Quantification of Biogenic Amines in Biofluids as Biomarkers of Various Disorders: A Review.

Authors:  Alina Plenis; Ilona Olędzka; Piotr Kowalski; Natalia Miękus; Tomasz Bączek
Journal:  J Clin Med       Date:  2019-05-09       Impact factor: 4.241

Review 5.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.

Authors:  Jonathan R Strosberg; Thorvardur R Halfdanarson; Andrew M Bellizzi; Jennifer A Chan; Joseph S Dillon; Anthony P Heaney; Pamela L Kunz; Thomas M O'Dorisio; Riad Salem; Eva Segelov; James R Howe; Rodney F Pommier; Kari Brendtro; Mohammad A Bashir; Simron Singh; Michael C Soulen; Laura Tang; Jerome S Zacks; James C Yao; Emily K Bergsland
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

Review 6.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 7.  Management of neuroendocrine tumors of unknown primary.

Authors:  Krystallenia Alexandraki; Anna Angelousi; Georgios Boutzios; Georgios Kyriakopoulos; Dimitra Rontogianni; Gregory Kaltsas
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 8.  Biochemical Testing in Neuroendocrine Tumors.

Authors:  Vidya Aluri; Joseph S Dillon
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-12       Impact factor: 4.741

9.  Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms.

Authors:  Anna Becker; Camilla Schalin-Jäntti; Outi Itkonen
Journal:  J Endocr Soc       Date:  2021-06-08

10.  The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.

Authors:  Rebecca Dobson; Malcolm I Burgess; Melissa Banks; D Mark Pritchard; Jiten Vora; Juan W Valle; Christopher Wong; Carrie Chadwick; Keith George; Brian Keevil; Joanne Adaway; Joy E S Ardill; Alan Anthoney; Uschi Hofmann; Graeme J Poston; Daniel J Cuthbertson
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.